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Conclusion
Malignant Hyperthermia
Aaron Roth, BSN, RN, CCRN
Introduction Pathophysiology Signs & Symptoms
Working in the medical and neuro 
intensive care unit and my future 
nursing profession as an anesthesia 
provider has sparked a spirit of inquiry 
in me regarding malignant 
hyperthermia. By choosing this 
research topic, I will begin to develop 
an understanding of this potentially 
fatal disease process and learn its 
clinical presentations and treatments. 
• Malignant hyperthermia is an 
inherited autosomal-dominant 
disease trait which occurs in 
individuals shortly after the 
induction of anesthesia who 
encounter inhaled general 
anesthetics or the neuromuscular 
blocking agent, succinylcholine. 
• Malignant hyperthermia is an 
emergent situation, and if it is not 
treated promptly and correctly, 
the outcome will be detrimental 
to the patient (Cain, Riess, 
Gettrust, & Novalija, 2014). 
MH is an emergent condition 
which initially manifests itself as a 
severe increase in CO2 production 
(hypercapnia) with abrupt 
hyperventilation and increased end 
tidal CO2. Also occurring is 
tachycardia, ventricular 
arrhythmias, and masseter spams. 
More signs and symptoms of MH 
include skin that is flush, 
generalized body rigidity, hypoxia, 
respiratory acidosis, and 
coagulopathy. Despite the name’s 
implication, a quick increase in 
temperature (> 38.8°C) is typically a 
late sign. As the MH crisis continues, 
there is detrimental skeletal muscle 
breakdown which results in 
rhabdomyolysis. Myoglobinemia, 
hyperkalemia, and an increased 
creatine phosphokinase all lead to 
an acute renal failure. If left 
untreated, the end stage of MH is 
displayed by circulatory collapse, 
multi-organ failure, and death 
(Schneiderbanger, Johannsen, 
Roewer, & Schuster, 2014). 
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It is of paramount importance for 
nurses to understand and be familiar with 
the treatment for MH. Anesthesia 
providers must maintain an accurate 
preoperative assessment. Gathering a 
precise temperature of the patient before 
anesthesia induction could help the 
anesthesia provider recognize the abrupt 
increase in temperature commonly found 
in MH. This could lead to prompt 
treatment of the disease process (Cain et 
al., 2014). When a crisis is recognized, 
inhaled anesthetics must cease as well as 
any other MH triggering drugs. The 
surgery or procedure should be 
discontinued and the patient monitored 
very closely. The primary treatment for 
MH is dantrolene sodium – a medication 
that is reconstituted with sterile water 
and pushed quickly through a large bore 
IV catheter. Because of the unique dosing 
of this medication and time-consuming 
demand for reconstitution, accurate and 
swift administration can pose as difficult 
(Seifert, Wahr, Pace, Cochrane, & Bagnola, 
2014). In addition to dantrolene
administration, nurses must also prepare 
cooling blankets and refrigerated crystalloid 
IV solution to counter attack the 
lethalhyperthermia involved with the crisis. 
The anesthesia provider should deliver 
100% FIO2 to avoid hypoxia and 
subsequent anaerobic metabolism, lactic 
acid accumulation, and ischemia (Dirksen et 
al., 2013). Sodium bicarbonate should be 
considered to treat acidosis. If cardiac arrest 
should occur, regular ACLS should 
commence. With education, experience, and 
familiarity of an MH crisis, nurses can 
effectively treat the disease which will not 
only save patient lives, but will also improve 
patient satisfaction and decrease patient 
length of stay in the hospital 
(Schneiderbanger et al., 2014). 
Implications for Nursing Care 
Malignant hyperthermia is a rare 
disease trait and can take place in a 
variety of settings. If not treated in a 
timely manner, the consequences 
will be dire. It is recommended that 
nurses and other healthcare 
personnel be properly educated on 
MH crises. By detecting the signs and 
symptoms associated with the 
disease, providers can efficiently 
remedy the crisis and save patient 
lives (Seifert, 2014). Since the 
discovery of dantrolene in 1975 and 
the advancement of genetics 
regarding MH, death rates dropped 
from about 80% to about 5% 
(Schneiderbanger et al., 2014). Today 
there is a MH group called the 
Malignant Hyperthermia Association 
of the United States which offers 
education and support for victims of 
MH. There is also a 24-hour hotline 
for people to call during an MH 
emergency (Dirksen et al., 2013). 
MH is an autosomal-dominant disease trait 
with incomplete penetrance and is associated 
with gene mutations of the ryanodine receptor 
1 (RYR1) and calcium voltage-gated channel 
subunit alpha1 S (CACNA1S). The RYR1 
functions to encode the skeletal muscle 
isoform of the calcium-release channel of the 
sarcoplasmic reticulum. CACNA1S functions to 
encode the alpha subunit of the L-type calcium 
channel isoform of the sarcolemma 
(Schneiderbanger et al., 2014). When 
functioning as intended, these genes are 
responsible to make proteins specifically for 
muscle movement. These proteins guide 
calcium in and out of the RYR1 ion channel in 
a coordinated technique with the end result 
being muscle contraction and/or relaxation. 
When there is a mutation in these genes, the 
channels are dysfunctional and lead to calcium 
channels that open too easily and close too 
slowly. This defect allows for a high influx of 
calcium into muscle cells which causes 
aberrant muscle contractions or rigidity. The 
increase in calcium concentration results in 
the processes which generate heat (leading to 
hyperthermia) and production of excess acid 
(leading to acidosis) and ultimately a 
hypermetabolic state (Riazi et al., 2014). 
Significance of Pathophysiology
It is critical to understand the pathophysiological significance of malignant hyperthermia because of the following:
• If left untreated, the outcome is almost certain death (Cain et al., 2014). 
• The cascade of consequences involved with MH are an increase of potassium (hyperkalemia), hyperthermia, and 
the release of myoglobin into the blood. 
• Myoglobinemia is catastrophic in that it disrupts the renal tubules which results in renal failure. 
• Hyperkalemia causes cardiac arrhythmias such as ventricular tachycardia or fibrillation which can lead to death.
• Hyperthermia is due to the hypermetabolic state and unsustaining APT expenditure (Schneiderbanger et al., 
2014).
• Respiratory and metabolic acidosis
• Blood coagulopathies (DIC) and internal hemorrhage
• Pulmonary edema
• Bowel ischemia
• multi-organ failure (Dirksen, Van Wicklin, Mashman, Neiderer, & Merritt, 2013). 
Figure 1: Ventricular Tachycardia 
Retrieved July 12, 2016, from http://lifeinthefastlane.com/ecg-library/ventricular-tachycardia/
Figure 2: “Uncontrolled myoplasmic Ca2+ release is the key to malignant hyperthermia. 
The most prominent cytosolic Ca2+ elevation results from the freeing of stored 
sarcoplasmic Ca2+ mediated by ryanodine receptor type 1 (RyR1). While volatile 
anesthetics stimulate Ca2+ release via RyR1, succinylcholine acts indirectly by 
activating the nicotinergic acetylcholine receptor (nAChR), a nonspecific cation channel, 
resulting in continuous local depolarisation. The depolarization can trigger propagated 
action potentials and will further activate the dihydropyridine receptors (DHPR, CaV1.1) 
leading to the gating of both Ca2+ release from the SR via RyR1 and L-type Ca2+ current 
from the extracellular space.” Graphic with text sourced from 
http://www.apsf.org/newsletters/html/2015/June/01_MHIQ.htm
Figure 3: Dantrolene sodium medication label. “Administer dantrolene by 
intravenous push at a minimum dose of 1 mg/kg. If manifestations of MH 
continue, administer additional intravenous boluses up to the maximum 
cumulative dosage of 10 mg/kg. If the symptoms reappear, repeat 
dantrolene dosing by intravenous push starting with 1 mg/kg.”
Graphic with text sourced from 
https://www.drugs.com/pro/ryanodex.html
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